The present invention relates to a novel crystalline form of lenbatynib mesylate and a process for its preparation. The novel crystalline form of the mesylate salt provided by the present invention can be used for the treatment of invasive and differentiated thyroid cancer. The novel crystalline form of mesylate provided by the present invention has good solubility and stability, a remarkable purification effect, a simple production method and low cost, so that it can be used for optimization and development of the drug in the future It has important value in terms of.Embedded image BACKGROUND OF THE INVENTION本発明はレンバチニブメシル酸塩の新規結晶形及びその製造方法に関する。本発明によって提供するメシル酸塩の新規結晶形は浸潤性、分化型甲状腺癌の治療に使用できる。本発明によって提供するメシル酸塩の新規結晶形は溶解性及び安定性が良好で、精製効果が顕著であり、製造方法が簡単で、コストが低いため、将来の当該薬物の最適化及び開発の面で重要な価値を持っている。【化1】【選択図】図1
